tetano
Editor, Senior Moderator
Immunol Cell Biol
. 2021 Jul 26.
doi: 10.1111/imcb.12495. Online ahead of print.
Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19
Michael S Abers[SUP] 1 [/SUP], Lindsey B Rosen[SUP] 1 [/SUP], Ottavia M Delmonte[SUP] 1 [/SUP], Elana Shaw[SUP] 1 [/SUP], Paul Bastard[SUP] 2 3 4 [/SUP], Luisa Imberti[SUP] 5 [/SUP], Virginia Quaresima[SUP] 5 [/SUP], Andrea Biondi[SUP] 6 [/SUP], Paolo Bonfanti[SUP] 7 [/SUP], Riccardo Castagnoli[SUP] 1 8 [/SUP], Jean-Laurent Casanova[SUP] 9 10 3 4 [/SUP], Helen C Su[SUP] 1 [/SUP], Luigi D Notarangelo[SUP] 1 [/SUP], Steven M Holland[SUP] 1 [/SUP], Michail S Lionakis[SUP] 1 [/SUP]
Affiliations
Abstract
Type-I interferons (IFNs) mediate antiviral activity and have emerged as important immune mediators during coronavirus disease 19 (COVID-19). Several lines of evidence suggest that impaired type-I IFN signaling may predispose to severe COVID-19. However, the pathophysiologic mechanisms that contribute to illness severity remains unclear. In the present study, our goal was to gain insight into how type-I IFNs influence patient outcomes in patients with COVID-19. To achieve this goal, we compared clinical outcomes between 26 patients with neutralizing type-I IFN autoantibodies (AAbs) and 192 patients without AAbs who were hospitalized for COVID-19 at three Italian hospitals. The presence of circulating AAbs to type-I IFNs was associated with an increased risk of admission to the intensive care unit and a delayed time to viral clearance. However, survival was not adversely affected by the presence of type-I IFN AAbs. Our findings provide further support for the contribution of type-I IFN AAbs in impairing host antiviral defense and promoting the development of critical COVID-19 pneumonia in SARS-CoV-2-infected individuals.
Keywords: Immunological deficiency syndromes; Infectious diseases; Innate immunity; translational immunology; viral infection.
. 2021 Jul 26.
doi: 10.1111/imcb.12495. Online ahead of print.
Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19
Michael S Abers[SUP] 1 [/SUP], Lindsey B Rosen[SUP] 1 [/SUP], Ottavia M Delmonte[SUP] 1 [/SUP], Elana Shaw[SUP] 1 [/SUP], Paul Bastard[SUP] 2 3 4 [/SUP], Luisa Imberti[SUP] 5 [/SUP], Virginia Quaresima[SUP] 5 [/SUP], Andrea Biondi[SUP] 6 [/SUP], Paolo Bonfanti[SUP] 7 [/SUP], Riccardo Castagnoli[SUP] 1 8 [/SUP], Jean-Laurent Casanova[SUP] 9 10 3 4 [/SUP], Helen C Su[SUP] 1 [/SUP], Luigi D Notarangelo[SUP] 1 [/SUP], Steven M Holland[SUP] 1 [/SUP], Michail S Lionakis[SUP] 1 [/SUP]
Affiliations
- PMID: 34309902
- DOI: 10.1111/imcb.12495
Abstract
Type-I interferons (IFNs) mediate antiviral activity and have emerged as important immune mediators during coronavirus disease 19 (COVID-19). Several lines of evidence suggest that impaired type-I IFN signaling may predispose to severe COVID-19. However, the pathophysiologic mechanisms that contribute to illness severity remains unclear. In the present study, our goal was to gain insight into how type-I IFNs influence patient outcomes in patients with COVID-19. To achieve this goal, we compared clinical outcomes between 26 patients with neutralizing type-I IFN autoantibodies (AAbs) and 192 patients without AAbs who were hospitalized for COVID-19 at three Italian hospitals. The presence of circulating AAbs to type-I IFNs was associated with an increased risk of admission to the intensive care unit and a delayed time to viral clearance. However, survival was not adversely affected by the presence of type-I IFN AAbs. Our findings provide further support for the contribution of type-I IFN AAbs in impairing host antiviral defense and promoting the development of critical COVID-19 pneumonia in SARS-CoV-2-infected individuals.
Keywords: Immunological deficiency syndromes; Infectious diseases; Innate immunity; translational immunology; viral infection.